Ortin Global Ltd
Incorporated in 1986, Ortin Laboratories Ltd manufactures pharmaceutical formulations.[1]
- Market Cap ₹ 12.9 Cr.
- Current Price ₹ 15.9
- High / Low ₹ 21.3 / 10.7
- Stock P/E
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Promoter holding is low: 1.23%
- Promoter holding has decreased over last 3 years: -6.13%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -11% |
| 3 Years: | -7% |
| 1 Year: | 13% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Number of operating manufacturing units units ・Standalone data |
|
|||||||
| Number of employees on rolls employees ・Standalone data |
||||||||
| Top product contribution to total turnover % of turnover ・Standalone data |
||||||||
| Manufacturing share of total revenue % of revenue ・Standalone data |
||||||||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 14.08.2026
- Board approved unaudited Q1 FY2026-27 results; net loss Rs 33.79 lakh, limited review completed.
-
Unaudited Financial Results For The Quarter Ended 30.06.2026
- Board approved unaudited Q1 FY2026-27 results on 14.08.2026; loss widened to Rs 33.79 lakh.
-
Board Meeting Intimation for Meeting To Be Held On 14.08.2026
- Board meeting on 14 Aug 2026 to consider Q1 FY2026-27 unaudited results; trading window closed from 1 Jul 2026.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Submitted Regulation 74(5) compliance certificate for quarter ended 30 June 2026.
-
Post-Offer Advertisement
- Post-offer advertisement for Parveen Satija's 26% open offer at ₹14.65; only 226 shares accepted.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
Business Overview:[1]
OLL is engaged in the manufacturing and trading of pharmaceuticals, drugs, and Intermediates and is also engaged in real estate.